MiR-1290 promotes myoblast differentiation and protects against myotube atrophy via Akt/p70/FoxO3 pathway regulation
Abstract Background Sarcopenia is a common skeletal disease related to myogenic disorders and muscle atrophy. Current clinical management has limited effectiveness. We sought to investigate the role of miR-1290 in myoblast differentiation and muscle atrophy. Methods By transfecting miR-1290 into C2C12 cells, we investigated whether miR-1290 regulates myogenesis and myotube atrophy via AKT/P70 signaling pathway. MHC staining was performed to assess myoblast differentiation. Differentiation-related MHC, Myod, and Myog protein levels, and atrophy-related MuRF1 and atrogin-1 were explored by western blot. An LPS-induced muscle atrophy rat model was developed. RT-PCR was conducted to analyze miR-1290 serum levels in muscle atrophy patients and normal controls (NCs). Results The miR-1290 transfection increased MHC-positive cells and MHC, Myod, and Myog protein levels in the miR-1290 transfection group, demonstrating that miR-1290 promoted C2C12 myoblast differentiation. Myotube diameter in the miR-1290 transfection group was higher than in the TNF-α-induced model group. Western blot analysis showed decreased MuRF1 and atrogin-1 levels in the miR-1290 transfection group compared with the model group, demonstrating that miR-1290 protected against myoblast cellular atrophy. Luciferase assay and western blot analysis showed that miR-1290 regulation was likely caused by AKT/p70/FOXO3 phosphorylation activation. In the LPS-induced muscle atrophy rat model, miR-1290 mimics ameliorated gastrocnemius muscle loss and increased muscle fiber cross-sectional area. Clinically, miR-1290 serum level was significantly decreased in muscle atrophy patients. Conclusions We found that miR-1290 enhances myoblast differentiation and inhibits myotube atrophy through Akt/p70/FoxO3 signaling in vitro and in vivo. In addition, miR-1290 may be a potential therapeutic target for sarcopenia treatment..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Skeletal Muscle - 11(2021), 1, Seite 12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ji Che [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Akt/P70/FoxO3 |
|---|
| doi: |
10.1186/s13395-021-00262-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ057052069 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ057052069 | ||
| 003 | DE-627 | ||
| 005 | 20230308205558.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13395-021-00262-9 |2 doi | |
| 035 | |a (DE-627)DOAJ057052069 | ||
| 035 | |a (DE-599)DOAJ9908b0d48cf149989a8c5de494e67a5a | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC925-935 | |
| 100 | 0 | |a Ji Che |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MiR-1290 promotes myoblast differentiation and protects against myotube atrophy via Akt/p70/FoxO3 pathway regulation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Sarcopenia is a common skeletal disease related to myogenic disorders and muscle atrophy. Current clinical management has limited effectiveness. We sought to investigate the role of miR-1290 in myoblast differentiation and muscle atrophy. Methods By transfecting miR-1290 into C2C12 cells, we investigated whether miR-1290 regulates myogenesis and myotube atrophy via AKT/P70 signaling pathway. MHC staining was performed to assess myoblast differentiation. Differentiation-related MHC, Myod, and Myog protein levels, and atrophy-related MuRF1 and atrogin-1 were explored by western blot. An LPS-induced muscle atrophy rat model was developed. RT-PCR was conducted to analyze miR-1290 serum levels in muscle atrophy patients and normal controls (NCs). Results The miR-1290 transfection increased MHC-positive cells and MHC, Myod, and Myog protein levels in the miR-1290 transfection group, demonstrating that miR-1290 promoted C2C12 myoblast differentiation. Myotube diameter in the miR-1290 transfection group was higher than in the TNF-α-induced model group. Western blot analysis showed decreased MuRF1 and atrogin-1 levels in the miR-1290 transfection group compared with the model group, demonstrating that miR-1290 protected against myoblast cellular atrophy. Luciferase assay and western blot analysis showed that miR-1290 regulation was likely caused by AKT/p70/FOXO3 phosphorylation activation. In the LPS-induced muscle atrophy rat model, miR-1290 mimics ameliorated gastrocnemius muscle loss and increased muscle fiber cross-sectional area. Clinically, miR-1290 serum level was significantly decreased in muscle atrophy patients. Conclusions We found that miR-1290 enhances myoblast differentiation and inhibits myotube atrophy through Akt/p70/FoxO3 signaling in vitro and in vivo. In addition, miR-1290 may be a potential therapeutic target for sarcopenia treatment. | ||
| 650 | 4 | |a miR-1290 | |
| 650 | 4 | |a Myoblast differentiation | |
| 650 | 4 | |a Atrophy | |
| 650 | 4 | |a Akt/P70/FoxO3 | |
| 653 | 0 | |a Diseases of the musculoskeletal system | |
| 700 | 0 | |a Cuidi Xu |e verfasserin |4 aut | |
| 700 | 0 | |a Yuanyuan Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Peiyu Jia |e verfasserin |4 aut | |
| 700 | 0 | |a Qi Han |e verfasserin |4 aut | |
| 700 | 0 | |a Yantao Ma |e verfasserin |4 aut | |
| 700 | 0 | |a Xiaolei Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Yongjun Zheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Skeletal Muscle |d BMC, 2011 |g 11(2021), 1, Seite 12 |w (DE-627)DOAJ000049387 |x 20445040 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g pages:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13395-021-00262-9 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/9908b0d48cf149989a8c5de494e67a5a |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13395-021-00262-9 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2044-5040 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 1 |h 12 | ||